| 43.11 -0.63 (-1.44%) | 08-28 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 51.09 |
1-year : | 53.17 |
| Resists | First : | 43.74 |
Second : | 45.52 |
| Pivot price | 43.31  |
|||
| Supports | First : | 40.86 |
Second : | 34 |
| MAs | MA(5) : | 43.12 |
MA(20) : | 43.01 |
| MA(100) : | 38.78 |
MA(250) : | 43.14 |
|
| MACD | MACD : | 0.6 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 50.3 |
D(3) : | 50.3 |
| RSI | RSI(14): 53 |
|||
| 52-week | High : | 57.3 | Low : | 32.23 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ QGEN ] has closed above bottom band by 43.6%. Bollinger Bands are 28.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 44.09 - 44.3 | 44.3 - 44.48 |
| Low: | 42.4 - 42.69 | 42.69 - 42.93 |
| Close: | 42.7 - 43.14 | 43.14 - 43.5 |
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Fri, 28 Aug 2026
Could Qiagen (QGEN) Stock Win as Its FDA Clearance Opens a New Diagnostics Market? - Yahoo Finance
Thu, 27 Aug 2026
QIAGEN's new lab system can process up to 96 samples in four batches - Stock Titan
Wed, 26 Aug 2026
QGEN Stock Slumps After-Hours On Guidance Cut Tied To Weak TB Test Demand - Stocktwits
Tue, 25 Aug 2026
Two potential buyers begin formal due diligence in Qiagen sales process - report (QGEN:NYSE) - Seeking Alpha
Mon, 24 Aug 2026
Qiagen NV (QGEN) Stock Down 5.2% -- Now Undervalued? GF Score: 7 - GuruFocus
Mon, 24 Aug 2026
Qiagen (NYSE:QGEN) Sees Large Volume Increase - Here's Why - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 207 (M) |
| Shares Float | 205 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 80.6 (%) |
| Shares Short | 8,230 (K) |
| Shares Short P.Month | 6,610 (K) |
| EPS | 1.97 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.26 |
| Profit Margin | 19.4 % |
| Operating Margin | 26.3 % |
| Return on Assets (ttm) | 5.8 % |
| Return on Equity (ttm) | 11.9 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 6.73 |
| Sales Per Share | 10.16 |
| EBITDA (p.s.) | 3.55 |
| Qtrly Earnings Growth | 13.6 % |
| Operating Cash Flow | 654 (M) |
| Levered Free Cash Flow | 373 (M) |
| PE Ratio | 21.88 |
| PEG Ratio | 1.1 |
| Price to Book value | 2.65 |
| Price to Sales | 4.23 |
| Price to Cash Flow | 13.6 |
| Dividend | 0.34 |
| Forward Dividend | 0 |
| Dividend Yield | 0.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|